Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients
Abstract Objective Cell division cycle 42 (CDC42) regulates prostate cancer growth and metastasis. This study aimed to evaluate the change in serum CDC42 during treatment and its association with the clinical features and prognosis in abiraterone plus prednisone treated metastatic castration-resista...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-03-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02130-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|